Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma

Annals of Oncology

Volumn 10, Issue 1, 1999, Pages 59-64

  Lazzarino, M ^a,b   Orlandi, E ^a   Montillo, M ^c   Tedeschi, A ^c   Pagnucco, G ^a   Astori, C ^a   Corso, A ^a   Brusamolino, E ^a   Simoncini, L ^b   Morra, E ^c   Bernasconi, C ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Fludarabine; Non Hodgkin's lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CLINICAL ARTICLE; DNA DAMAGE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CD4 LYMPHOCYTE COUNT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODES; LYMPHOMA, LOW-GRADE; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; VIDARABINE;

EID: 0033065253     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008376728894     Document Type: Article

References (22)

1. Keating MJ, O'Brien S, Plunkett W et al. Fludarabine phosphate: A new active agent in hematologic malignancies. Semin Hematol 1994; 31: 28-39.
2. Whelan JS, Davis CL, Rule S et al. Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer 1991; 64: 120-3.
3. Redman JR, Cabanillas F, Velasquez WS et al. Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma. J Clin Oncol 1992; 10: 790-4.
4. Hiddemann W, Unterhalt M, Pott C et al. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: A phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group. Semin Oncol 1993; 20 (Suppl 7): 28-31.
5. Hochster HS, Kim KM, Green MD et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study. J Clin Oncol 1992; 10: 28-32.
6. Zinzani PL, Lauria F, Rondelli D et al. Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann Oncol 1993; 4: 575-8.
7. Falkson CI. Fludarabine: A phase II trial in patients with previously treated low-grade lymphoma. Am J Clin Oncol 1996; 19: 268-70.
8. Decaudin D, Bosq J, Tertian G et al. Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 1998; 16: 579-83.
9. Solal Celigny P, Brice P, Brousse N et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1996; 14: 514-9.
10. Plunkett W, Huang P, Gandhi V. Metabolism and action of fludarabine phosphate. Semin Oncol 1990; 17 (Suppl 8): 3-17.
11. McLaughlin P, Hagemeister FB, Swan F Jr et al. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 1994; 12: 575-9.
12. McLaughlin P, Hagemeister FB, Romaguera JE et al. Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma. J Clin Oncol 1996; 14: 1262-8.
13. Zinzani PL, Bendandi M, Magagnoli M et al. Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. Ann Oncol 1997; 8: 379-83.
14. Zinzani PL, Bendandi M, Gherlinzoni F et al. FLU-ID (fludarabine and idarubicin) regimen as salvage therapy in pretreated low-grade non-Hodgkin's lymphoma. Haematologiza 1996; 81: 168-71.
15. O'Brien S, Kantarjian H, Beran M et al. Fludarabine (FAMP) and cyclophosphamide (CTX) therapy in chronic lymphocytic leukemia (CLL). Second Meeting of the European Haematology Association, Paris, France, 1996. Br J Haematol 1996: 93 (Suppl 2): 116 (Abstr).
16. Flinn IW, Byrd JC, Seifter E et al. Fludarabine and cyclophosphamide as first therapy for indolent lymphoproliferative disorders: Response rates and toxicity. Blood 1996; 88 (Suppl 1): 589a (Abstr).
17. Hochster H, Oken M, Winter J et al. Prolonged time to progression (TTP) in patients with low grade lymphoma (LGL) treated with cyclophosphamide (C) and fludarabine (F) [ECOG 1491]. Proc Am Soc Clin Oncol 1998; 17: 17a (Abstr).
18. Gerna G, Furione M, Baldanti F et al. Comparative quantitation of human Cytomegalovirus DNA in blood leukocytes and plasma of transplant and AIDS patients. J Clin Microbiol 1994; 32: 2709-17.
19. Younes A, Rodriguez MA, McLaughlin P et al. Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma. Leuk Lymph 1997; 26: 77-82.
20. Shields DJ, Byrd JC, Abbondanzo SL et al. Detection of Epstein Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment. Mod Pathol 1997; 10: 1151-9.
21. Fend F, Hittmair A, Rogatsch H et al. Seminoma positive for Epstein Barr virus by the polymerase chain reaction: Viral RNA transcripts (Epstein-Barr-encoded small RNAs) are present in intratumoral lymphocytes but absent from the neoplastic cells. Mod Pathol 1995; 8: 622-5.
22. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-63.